Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | XmAb22841 |
Trade Name | |
Synonyms | Pavunalimab |
Drug Descriptions |
Pavunalimab (XmAb22841), is a bispecific antibody that targets CTLA4 and LAG3, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary). |
DrugClasses | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 LAG3 Antibody 18 |
CAS Registry Number | 2329669-78-3 |
NCIT ID | C159530 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Izuralimab + XmAb22841 | Izuralimab XmAb22841 | 0 | 1 |
Pembrolizumab + XmAb22841 | Pembrolizumab XmAb22841 | 0 | 1 |
XmAb22841 | XmAb22841 | 0 | 1 |